Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-103521
Filing Date
2025-08-06
Accepted
2025-08-06 07:00:20
Documents
67
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q nams-20250630.htm   iXBRL 10-Q 1986022
2 EX-10.1 nams-ex10_1.htm EX-10.1 38809
3 EX-10.2 nams-ex10_2.htm EX-10.2 119923
4 EX-31.1 nams-ex31_1.htm EX-31.1 17320
5 EX-31.2 nams-ex31_2.htm EX-31.2 17277
6 EX-32.1 nams-ex32_1.htm EX-32.1 9634
7 EX-32.2 nams-ex32_2.htm EX-32.2 9608
  Complete submission text file 0000950170-25-103521.txt   8266314

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT nams-20250630.xsd EX-101.SCH 1110784
70 EXTRACTED XBRL INSTANCE DOCUMENT nams-20250630_htm.xml XML 1576796
Mailing Address GOOIMEER 2-35 NARRDEN P7 1411 DC
Business Address GOOIMEER 2-35 NARRDEN P7 1411 DC 35 206 2971
NewAmsterdam Pharma Co N.V. (Filer) CIK: 0001936258 (see all company filings)

EIN.: 000000000 | State of Incorp.: P7 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-41562 | Film No.: 251187373
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)